Culture medium for screening or enrichment of methicillin-resistant
The invention relates to culture medium for screening or enrichment of methicillin-resistant Staphylococcus aureus (MRSA), which medium comprises a combination of at least two cephalosporins.
1. A culture medium for screening or enrichment of methicillin-resistant Staphylococcus aureus (MRSA) comprising a combination of cephalosporins selected from the group consisting of cefotetan (CTT) and ceftriaxone (CRO); cefotetan (CTT) and cefpodoxime (CPD); cefsulodin (CFS) and ceftriaxone (CRO); cefsulodin (CFS) and cefepime (FEP); and cefotetan (CTT) and ceftiofur (XLN) and wherein each cephalosporin is present in a concentration of between 1.0 mg/l and 3.5 mg/l.
2. The culture medium according to claim 1 , said medium further comprising a chromogenic agent.
3. The culture medium according to claim 2 , wherein the chromogenic agent is 6 chloro 3-indoxyl phosphate.
4. The culture medium according to claim 1 , wherein said culture medium is an agar culture medium.
5. The culture medium according to claim 1 , wherein said culture medium is a broth.
6. The culture medium according to claim 1 , said culture medium comprising:
a) 1.1 to 2.5 mg/l of cefotetan and 1.5 to 2.5 mg/l of ceftriaxone;
b) 1.75 mg/l cefotetan and 2.4 mg/l ceftriaxone; or
c) 2.4 mg/l cefotetan and 2.4 mg/l ceftriaxone.
7. The culture medium according to claim 1 , said culture medium comprising:
2 mg/l cefotetan and 2 mg/l ceftriaxone,
2.4 mg/l cefotetan and 2.4 mg/l ceftriaxone,
2 mg/l cefotetan and 1.5 mg/l cefpodoxime,
2.5 mg/l cefotetan and 1.8 mg/l cefpodoxime,
3.5 mg/l cefsulodin and 2 mg/l ceftriaxone, or
3 mg/l cefsulodin and 2 mg/l cefepime.
8. The culture medium according to claim 1 , said culture medium further comprising cefoperazone.
9. The culture medium according to claim 8 , wherein said culture medium comprising cefoperazone is at a concentration of between 0.1 mg/l to 3 mg/l.
10. The culture medium of claim 1 , wherein said combination of cephalosporins is cefotetan (CTT) and ceftriaxone (CRO).
11. The culture medium of claim 1 , wherein said combination of cephalosporins is cefotetan (CTT) and cefpodoxime (CPD).
12. The culture medium of claim 1 , wherein said combination of cephalosporins is cefsulodin (CFS) and ceftriaxone (CRO).
13. The culture medium of claim 1 , wherein said combination of cephalosporins is cefsulodin (CFS) and cefepime (FEP).
14. The culture medium of claim 1 , wherein said combination of cephalosporins is cefotetan (CTT) and ceftiofur (XLN).
15. The culture medium of claim 1 , wherein each cephalosporin is present in a concentration of between 1.25 mg/l and 3.5 mg/l.
16. The culture medium of claim 1 , wherein each cephalosporin is present in a concentration of between 1.1 mg/l and 3.5 mg/l.
17. A method for screening or enriching methicillin-resistant Staphylococcus aureus (MRSA) in a culture medium, which method comprises (i) inoculating the culture medium according to claim 1 , with bacteria to test, and (ii) culturing said bacteria in said culture medium.
18. The method according to claim 17 , wherein the bacteria to test are in the form of a clinical sample.
19. The method according to claim 18 , wherein said clinical sample is a nasal swab, a wound sample or a blood sample.
20. A method for screening or enriching methicillin-resistant Staphylococcus aureus (MRSA) in a culture medium, which method comprises (i) inoculating the culture medium according to claim 2 , with bacteria to test, (ii) culturing said bacteria on said culture medium, and (iii) identifying the presence of MRSA strains on said culture medium.